| Literature DB >> 15711048 |
Christian Mottet1, Pascal Juillerat, Jean-Jacques Gonvers, Pierre Michetti, Bernard Burnand, John-Paul Vader, Christian Felley, Florian Froehlich.
Abstract
Symptomatic gastroduodenal manifestations of Crohn's disease (CD) are rare, with less than 4% of patients being clinically symptomatic. Gastroduodenal involvement may, however, be found endoscopically in 20% and in up to 40% of cases histologically, most frequently as Helicobacter pylori-negative focal gastritis, usually in patients with concomitant distal ileal disease. In practice, the activity of concomitant distal CD usually determines the indication for therapy, except in the presence of obstructive gastroduodenal symptoms. With the few data available, it seems correct to say that localized gastroduodenal disease should be treated with standard medical therapy used for more distal disease, with the exception of sulfasalazine and mesalanine with pH-dependent release. Presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider. Copyright (c) 2005 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15711048 DOI: 10.1159/000083871
Source DB: PubMed Journal: Digestion ISSN: 0012-2823 Impact factor: 3.216